Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paolo Rivela
Observed names:
P. Rivela,
Rivela P.
Institution:
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Observed institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo,
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
ORCID:
0000-0003-1035-4972
Observed ORCID:
0000-0003-1035-4972
OpenAlex ID:
A5045641392
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs
2021
·
Candida Vitale
, Chiara Salvetti
, et al.
·
Blood
·
47
PDF
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
2024
·
Gianluca Cavallaro
, Anna Grassi
, et al.
·
Blood Cancer Journal
·
12
PDF
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice
2023
·
Rita Tavarozzi
, Giulia Zacchi
, et al.
·
Cancers
·
12
PDF
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
2022
·
Lydia Scarfò
, Silvia Heltai
, et al.
·
Blood
·
12
PDF
SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia
2022
·
Enrico Tiacci
, Alessandro Mancini
, et al.
·
British Journal of Haematology
·
7
The role of Bruton’s kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib
2023
·
Gioacchino Catania
, Rita Tavarozzi
, et al.
·
Journal of Basic and Clinical Physiology and Pharmacology
·
5
Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study
2023
·
Elisa Albi
, Lydia Scarfo
, et al.
·
Blood
·
3
PDF
The black swan: a case of central nervous system graft-versus-host disease
2023
·
Sara Butera
, Rita Tavarozzi
, et al.
·
Journal of Basic and Clinical Physiology and Pharmacology
·
3
Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study
2026
·
Fabbri N.
, Casadei B.
, et al.
·
Institutional Research Information System (University of Udine)
·
2
461 | Outcomes of Car T‐cell Therapy in Transformed Indolent Non‐hodgkin Lymphomas and De Novo Dlbcl: a Comparative Analysis From the Italian Car T‐sie Study
2025
·
Nicole Fabbri
, Beatrice Casadei
, et al.
·
European Journal of Cancer
·
2
PDF
P646: Venetoclax Retreatment After Mrd-guided Venetoclax +/- Ibrutinib: the Improve Study Cohort
2023
·
Lydia Scarfò
, Silvia Heltai
, et al.
·
HemaSphere
·
2
Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis
2022
·
Monia Marchetti
, Paolo Rivela
, et al.
·
Journal of Clinical Medicine
·
2
PDF
VULVO‐Vaginal Chronic Graft‐Versus‐Host Disease Assessment: A Single‐Center Prospective Observational Study
2026
·
Francesca Palmisano
, Chiara Cannici
, et al.
·
European Journal Of Haematology
·
1
PDF
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation
2024
·
Chiara Nozzoli
, Martina Pucillo
, et al.
·
Transplantation and Cellular Therapy
·
1
Circulating Plasma Cells Evaluation Before and After CAR T-cell Therapy as a Dynamic Factor for Response Assessment
2025
·
Federico Monaco
, Carolina Gandolfo
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
2025
·
Francesca Perutelli
, Elia Boccellato
, et al.
·
British Journal of Haematology
PDF
Immunoterapia adottiva mediante Infusione di Linfociti da Donatore (DLI) dopo trapianto allogenico di cellule staminali emopoietiche e monitoraggio del chimerismo
2024
·
Camilla Zani
, Roberta Neri
, et al.
·
Working Paper of Public Health
PDF
Monitoraggio delle complicanze da tossicità nei pazienti sottoposti a CAR-T: studio osservazionale, prospettico
2022
·
Francesca Palmisano
, Roberta Di Matteo
, et al.
·
Working Paper of Public Health
PDF
Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
2022
·
Gianluca Cavallaro
, Anna Grassi
, et al.
·
Blood
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs
2019
·
Candida Vitale
, Chiara Salvetti
, et al.
·
Blood
Show more works
View as search
Works count:
21
Citation count:
111
H-index:
5
I10-index:
4
Year
Topic
Type